However, consistent with the recognized therapeutic effect of OCA, these common TFs are related not only to hepatic steatosis and steatohepatitis improvements (ATF6, HBP1, BTG1, SAP18, PPARD, PPARG, BIRC2), but also to anti-fibrotic effects (FOXO1, INSR, KLF6) and blocking of disease progression (DACH1, RYBP, ZFP36L1). Here, KLF6 is linked to fatty liver disease.